November’s Four Cancer Campaigns Spotlight Genetic Risk and Testing Access

This November carries four separate cancer awareness campaigns at once — Neuroendocrine Tumors Awareness Month, Gastric Cancer Awareness Month, Lung Cancer Awareness Month and Pancreatic Cancer Awareness Month — and the reporting behind them points to one thread running through several of the diseases: inherited genetic risk that can raise the odds of more than one cancer in the same person.

The backdrop matters for timing. October belonged to Breast Cancer Awareness Month, which focused public attention on symptoms, risk factors and available resources for a single disease. November’s four campaigns take a wider view, and their overlap is what connects them to the question of testing.

One gene, several cancers

Cancer has many causes, and two people can develop the same form of the disease for entirely different reasons. Age, lifestyle factors and environmental exposures all play a part, and inherited genetic variants are another piece of the puzzle — one whose influence can extend past a single cancer type.

Some inherited variants increase stomach cancer risk, while others are linked to higher risks of lung or pancreatic cancer. Several of those variants overlap, which means an increased lifetime risk of two or more cancers.

The presence of a mutated gene does not automatically lead to a diagnosis. What it does is give a person and their doctor another source of information to weigh alongside personal and family medical history, which is where hereditary testing enters the conversation.

Testing that looks for risk, not disease

Hereditary cancer testing is not a screening procedure. A screening procedure is designed to look for signs of cancer; a hereditary test instead detects genetic variants associated with increased cancer risk.

The distinction has practical consequences. A genetic mutation can be present in someone who remains cancer-free throughout life, while a person carrying no such mutation may still receive a cancer diagnosis. Neither result settles the question on its own; both add to the picture a healthcare provider uses when deciding whether earlier or more frequent screening makes sense, particularly where a family history of cancer is evaluated.

jscreen’s 63-gene panel

At-home testing programs have made genetic testing more accessible over the last few years. Among them is jscreen, a national nonprofit public health initiative that offers hereditary cancer testing to individuals nationwide.

The program examines 63 genes associated with hereditary cancer syndromes and increased cancer risk. Those taking part order a kit through the internet, provide a saliva sample from home and send it to a clinical laboratory for analysis, and the results arrive within three to four weeks. A consultation with a certified genetic counselor is also available to review their findings and discuss potential next steps with a healthcare provider.

What the four November campaigns share is education: which symptoms to watch for and what to discuss with a healthcare provider. The counseling step at jscreen reflects the same logic — a test result is treated as input to a medical conversation rather than an answer in itself.

The campaigns run through November. Whether genetic testing becomes part of an individual’s screening decisions remains, as the awareness campaigns have shown, a matter for that person and their healthcare provider, informed by what the four awareness months set out to explain.

Photo of author

World Desk

World Desk at Archyde.

UK Jury Convicts Four Men in Drugged Wife Rape Case

Bond Yields Rise Globally but Fall to Record Lows in China